

An Evening with the Investigators: Perspectives on Key Questions and Emerging Research in the Management of Lymphoma and Multiple Myeloma (Video Program)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The results of the Phase III GALLIUM study comparing obinutuzumab/chemotherapy to rituximab/chemotherapy as induction followed by maintenance obinutuzumab or rituximab for patients with previously untreated, advanced indolent non-Hodgkin lymphoma demonstrated _____.
 - a. A significant increase in progression-free survival (PFS) with obinutuzumab and CVP, CHOP or bendamustine
 - b. A significant increase in PFS with obinutuzumab and CVP but not CHOP or bendamustine
 - c. A significant increase in overall survival with obinutuzumab maintenance therapy

2. Which of the following statements is true regarding CAR T-cell therapy in patients with diffuse large B-cell lymphoma?
 - a. CAR T-cell therapy requires debulking chemotherapy because it is not active in bulky disease
 - b. CAR T-cell therapy is most effective in frail patients unfit for allogeneic stem cell transplant
 - c. CAR T-cell therapy can produce durable remissions in patients with heavily refractory disease

3. Patients with chronic lymphocytic leukemia (CLL) and the 17p deletion typically acquire the deletion over the course of the disease and rarely present with del(17p) disease at up-front diagnosis or in the setting of first therapy.
 - a. True
 - b. False

4. Which of the following statements is true regarding carfilzomib therapy?
 - a. Neuropathy is a common adverse effect
 - b. Five percent of patients can develop transient cardiac-related events
 - c. The PFS benefit with carfilzomib is less than that with bortezomib in all settings

5. Which of the following statements is true regarding the Bcl-2 inhibitor venetoclax?
 - a. Tumor lysis syndrome is more common with venetoclax treatment for multiple myeloma than for CLL
 - b. Venetoclax has a higher response rate for patients with multiple myeloma with 11;14 translocations than for those without
 - c. Venetoclax is unlikely to be effective for patients with cyclin D overexpression